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PPARg Promotes Monocyte/Macrophage
Differentiation and Uptake of Oxidized LDL
the presence of high concentrations of LDL (Brown and
Goldstein, 1983). It is now clear that uptake of LDL by
foam cells ismediated by a group of cell surface proteins
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termed scavenger receptors. Brown and Goldstein and*The Salk Institute for Biological Studies
colleagues were the first to demonstrate that these re-²Howard Hughes Medical Institute
ceptors have virtually no affinity for native LDL and thatLa Jolla, California 92037
chemical modification of LDL is required for recognition³Department of Pathology
(Goldstein et al., 1979). While these initial studies utilizedUniversity of California
acetylated LDL as a ligand, the relevant chemical modifi-San Diego, California 92093
cation in vivo is likely to be oxidation (Steinberg et al.,§Departments of Pathology and Integrative Biology
1989, and references therein).University of Texas at Houston Medical School
A number of macrophage cell surface proteins haveHouston, Texas 77225
been identified that can specifically bind oxLDL. These
include the class A scavenger receptor (SR-A; Kodama
et al., 1988; Matsumoto et al., 1990), SR-BI (Acton etSummary
al., 1994), CD36 (Endemann et al., 1993), CD68 (Rampra-
sad et al., 1996), and CD32 (FcgRII; Stanton et al., 1992).The formation of foam cells from macrophages in the
While the in vivo relevance of some of these proteinsarterial wall is characterized by dramatic changes in
remains to bedetermined, recent data support an impor-lipid metabolism, including increased expression of
tant role for both SR-A and CD36 in the pathogenesisscavenger receptors and the uptake of oxidized low-
of atherosclerosis. Monocytes derived from mice defi-density lipoprotein (oxLDL). We demonstrate here that
cient inSR-A (Suzuki et al., 1997) or from humans lackingthe nuclear receptor PPARg is induced in human
functional CD36 (Nozaki et al., 1995) exhibit significantlymonocytes following exposure to oxLDL and is ex-
decreased uptake of oxLDL. While expression of SR-Apressed at high levels in the foam cells of atheroscle-
is restricted to macrophages, CD36 is also known to berotic lesions. Ligand activation of the PPARg:RXRa het-
expressed in platelets, adipose tissue, and mammaryerodimer in myelomonocytic cell lines induces changes
epithelium. Indeed, CD36 has been proposed to functioncharacteristic of monocytic differentiation and pro-
as an adhesion molecule in platelets (Asch et al., 1987)motes uptake of oxLDL through transcriptional induc-
and as a fatty acid transporter in adipose tissue (Abum-tion of the scavenger receptor CD36. These results
rad et al., 1993).
reveal a novel signaling pathway controlling differenti-
PPARg is a member of the nuclear hormone receptor
ation and lipid metabolism in monocytic cells, and sug-
superfamily that heterodimerizes with the retinoid X re-
gest that endogenous PPARg ligands may be important
ceptor (RXR) and functions as a transcriptional regulator
regulators of gene expression during atherogenesis. of genes linked to lipid metabolism. Known targets of
PPARg include the genes encoding the adipocyte fatty
Introduction acid binding protein aP2 (Tontonoz et al., 1994a), phos-
phoenolpyruvate carboxykinase (Tontonoz et al., 1995),
The deposition of cholesterol ester within cells of the lipoprotein lipase (Schoonjans et al., 1996), and the
artery wall is fundamental to the pathogenesis of athero- brown fat uncoupling protein UCP1 (Sears et al., 1996).
sclerosis (Brown and Goldstein, 1983; Steinberg et al., The thiazolidinedione class of antidiabetic drugs and
1989). Atherogenic cholesterol-rich diets lead to an in- 15-deoxy-D12,14-prostaglandin J2 (15d-PGJ2) have been
crease in monocyte adherence to arterial endothelium identified as ligands for this receptor, facilitating analy-
and their subsequent migration into the subendothelial sis of its biologic function (Forman et al., 1995a; Kliewer
space, where they take up large amounts of cholesterol et al., 1995; Lehmann et al., 1995). PPARg is expressed
ester. These cholesterol-laden macrophages are known at highest levels in adipose tissue and serves a central
as foam cells, and it is the accumulation of these cells regulator of the process of adipocyte differentiation
beneath the endothelium that forms the earliest grossly (Chawla et al., 1994; Tontonoz et al. 1994b). However,
recognizable atherosclerotic lesion, the fatty streak (Stary mounting evidence suggests that this transcription fac-
et al., 1994). An understanding of the mechanisms by tor may also play an important role in the regulation of
which monocytes accumulate LDL cholesterol is central lipid metabolism in other cell types, such as mammary
toan understanding of theearly stages of atherogenesis. and colonic epithelium (Mueller et al., 1998).
The observation that patients lacking functional LDL PPARg has been reported to be expressed in several
receptors still develop atherosclerotic lesions rich in myeloid leukemia cell lines (Greene et al., 1995), al-
foam cells led to the discovery of the ªscavenger path- though its biologic function in hematopoetic cells has
wayº for LDL uptake (Goldstein et al., 1979; Buja et al., not been defined. Given the established role of this nu-
1983). Macrophages express relatively few receptors for clear receptor as a regulator of adipocyte differentiation,
native LDL, and these receptors are down-regulated in we explored whether PPARg might serve a similar func-
tion in myelomonocytic cells. In the following work, we
outline a novel signaling pathway for the regulation of‖ To whom correspondence should be addressed.
# These authors contributed equally to this work. monocyte differentiation and lipid metabolism mediated
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Figure 1. Expression of PPARg in Peripheral Blood Monocytes and Tissue Macrophages
(A±C) Analysis of PPARg protein expression in 3T3-L1 cells by immunofluorescence microscopy. (A) Preimmune serum, (B and C) anti-PPARg.
(D) Analysis of PPARg protein expression in human peripheral blood monocytes.
(E and F) Localization of PPARg protein expression in murine lymph node by immunohistochemistry. Peroxidase activity was visualized by
Vector VIP substrate and sections were counterstained with 0.4% methylgreen.
Objective magnification 403 for (A), (B), (D), and (E) and 1003 for (C) and (F).
by the PPARg:RXR heterodimer. These findings suggest in tissue macrophages, we performed immunohisto-
chemistry on sections of murine lymph node. As shownan unexpected role for nuclear receptors in the patho-
in Figures 1E and 1F, the nuclei of the macrophages ingenesis of atherosclerosis.
these sections show strong staining (purple) for PPARg
(arrows). By contrast, no staining is seen in the lympho-
Results cyte nuclei.
Expression of PPARg Protein in Peripheral Blood Regulation of PPARg Expression during
Monocytes and Tissue Macrophages Myelomonocytic Differentiation
The expression of PPARg in spleen and myelomonocytic The human leukemia cell line HL60 was used to begin
leukemia cells (Greene et al., 1995), led us to search for to characterize the role of PPARg in monocytic cells.
its expression in normal peripheral blood monocytes HL60 cells display controlled differentiation along the
and tissue macrophages. To address this issue, we per- granulocyte or the monocyte lineage in response to vari-
formed immunofluorescence microscopy using immu- ous inductive signals. For example, retinoic acid recep-
noaffinity-purified antisera raised against the N terminus tor (RAR) ligands such as 9-cis retinoic acid and the
of human PPARg. The ability of this antisera to detect synthetic retinoid AM580 are inducers of HL60 granulo-
PPARg protein in cells was verified using cultured 3T3- cytic differentiation, while 1,25-dihydroxyvitamin D3 and
L1 preadipocytes, which have been shown to express TPA promote monocytic differentiation. Expression of
PPARg (Chawla et al., 1994; Tontonoz et al., 1994b). A PPARg mRNA during HL60 cell differentiation was ana-
low level of background cytoplasmic staining but no lyzed by Northern blotting. As shown in Figure 2A, a
nuclear staining was seen with preimmune sera (Figure 3- to 5-fold increase in PPARg expression was observed
1A). Distinct punctate nuclear staining of 3T3-L1 cells when HL60 cells were treated for 5 days with either 40
was seen with the PPARg antiserum (Figures 1B and nM 1,25-dihydroxyvitamin D3 or for 24 hr with 40 ng/ml
1C). Most of the cells in Figure 1B are undifferentiated TPA. No change in PPARg expression was seen after 5
preadipocytes and stain weakly for PPARg; however, a days of treatment with 40 nM AM580. Thus, expression
single differentiated adipocyte with obvious cytoplasmic of PPARg in this cell line is induced by agents known
lipid accumulation stains very strongly (arrow). This is to trigger monocytic differentiation.
consistent with the known differentiation-dependent ex-
pression of PPARg in 3T3-L1 cells. A similar pattern of PPARg and RXR Ligands Promote the Differentiation
punctate nuclear staining is observed in human periph- of Myelomonocytic Cells
eral blood monocytes with anti-PPARg antisera (Figure Next we asked whether ligand activation of the PPARg
pathway could influence maturation of HL60 cells. Cells1D). To determine whether PPARg was also expressed
PPARg and Foam Cell Differentiation
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expression of the lipopolysaccharide receptor CD14 is
selectively induced during monocytic differentiation (Lub-
bert et al., 1991). Following culture for 5 days in the
presence of various combinations of receptor-specific
ligands, surface antigen expression was analyzed by
flow cytometry. As expected, the RAR-specific retinoid
AM580 was an effective inducer of CD18 and CD11b,
but had only a small effect on CD14 expression (Figures
3A and 3B). In contrast, BRL49653, 15d-PGJ2, or LG268
alone induced CD18, CD11b, and CD14 expression, and
simultaneous treatment with PPARg and RXR ligands
had a synergistic effect on all three markers (Figure 3
and data not shown). The magnitude of the change in
surface CD14 expression is underscored by the distinct
shift in the fluorescence intensity of the counted popula-
tion (Figure 3B, insert).
To determine whether the expression of PPARg was
required for induction of monocyte markers by these
agonists, we examined their effect on the HL60-derived
leukemia cell line CDM-1. This cell line has an intact
RXR signaling pathway (Nagy et al., 1995); however, it
does not express PPARg (Figure 3C, insert). Treatment
of CDM-1 cells with 15d-PGJ2 and LG268 had no effect
Figure 2. Expression and Function of PPARgin HL60 Cells on CD11b, CD18, or CD14 expression (Figure 3C and
(A) Expression of PPARg is regulated during HL60 cell differentiation. data not shown), suggesting that PPARg is required
HL60 cells were cultured for 5 days in the presence of 30 nM 1,25- for the differentiation response to these compounds in
dihydroxyvitamin D3, 30 nM AM580 or for 24 hr in the presence of HL60 and related cell lines. Similarly, no effect on ex-40 ng/ml TPA. Total RNA (15 mg per lane) was analyzed by Northern
pression of these antigens was observed in KG-1 leuke-blotting using 32P-labeled cDNA probes. Equivalent amounts of in-
mia cells, which also lack PPARg expression (data nottact RNA were run in each lane as indicated by hybridization to a
36B4 cDNA probe. shown).
(B) PPARg and RXR ligands induce growth arrest and oxidative The effects of PPARg:RXR activation were also exam-
burst capacity in HL60 cells. HL60 cells were plated at a density of ined in the monocytic leukemia cell line THP-1, which
2 3 105 cells/ml and cultured for 5 days in the presence of one or can be induced to differentiate terminally into macro-
more of the following activators as indicated: 100 nM 9-cis retinoic
phage-like cells by treatment with TPA or 1,25-dihy-acid, 100 nM LG268, 3 mM 15d-PGJ2, or 5 mM BRL49653. On day
droxyvitamin D3. Again, treatment of THP-1 cells with3 and day 5, cell number was quantitated by hemocytometer, and
on day 5 an NBT reduction assay was performed. PPARg and RXR-specific ligands resulted in a syner-
gistic induction of surface CD14 expression (Figure 3D).
Note that this induction is equivalent in magnitude to
were cultured for 5 days in the presence of either 9-cis that seen with TPA, a known inducer of monocytic differ-
retinoic acid (9-cis RA; 100 mM), the natural PPARg li- entiation. As expected, an induction of CD14 expression
gand 15d-PGJ2 (3 mM), the synthetic PPARg ligand was also seen following treatment with 1,25-dihydroxy-
BRL49653 (5 mM), the RXR-specific retinoid LG268 (100 vitamin D3.
nM; Boehm et al., 1995), or the combination of a PPARg We also examined the ability of PPARg ligands to
ligand and LG268. As anticipated, HL60 cells treated modulate surface marker expression in primary cultures
with 9-cis RA exhibited a reduction in cell growth, an of human peripheral blood monocytes. As shown in Fig-
induction of oxidative burst capacity as measured by NBT ure 3E, treatment of monocytes with PPARg activators
reduction assay, and distinct changes in nuclear mor- from each of three different chemical classes, troglita-
phology (Figure 2B and data not shown). Unexpectedly, zone, 15d-PGJ2, or oxLDL (Nagy et al., 1998, this issue
the combination of 15d-PGJ2 and LG268 or BRL49653 of Cell) resulted in similar changes in CD14 expression.
and LG268 led to similar effects. Treatment with either These findings indicate that ligand activation of PPARg
15d-PGJ2, BRL49653, orLG268 alone had a lesser effect in monocytic cells promotes changes in surface marker
(Figure 2B and data not shown). No effect was observed expression characteristic of monocytic differentiation.
with the PPARa-specific activator Wy14,643 (5 mM) or
the PPARd ligand carbaprostacyclin (1 mM), either when
used alone or in combination with LG268 (data not Expression of PPARg Is Induced
by Exposure to Oxidized LDLshown). These observations suggested that activation
of the PPARg:RXR heterodimer represents a novel regu- Treatment of THP-1 cells with PPARg and RXR ligands
resulted in characteristic morphological changes, in-latory pathway for HL60 maturation.
To further characterize the effect of PPARg and RXR cluding a tendency to adhere to the culture dish and to
accumulate cytoplasmic lipid droplets (Figures 4A andligands on HL60 cells, we examined differentiation-
dependent surface marker expression. Expression of 4B). This observation suggested that PPARg might func-
tion in monocytic cells to regulate genes involved inthe integrins CD18 and CD11b is up-regulated during
differentiation to either granulocytes or monocytes, while lipid metabolism. Since the foam cells of atherosclerotic
Cell
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Figure 3. Induction of Differentiation-Linked Surface Marker Expression in HL60 and THP-1 Cells by PPARg and RXR Ligands
HL60, CDM-1, and THP-1 cells were cultured for 6 days in the presence of one or more of the following activators as indicated: 100 nM
LG268, 5 mM BRL49653, 3 mM 15d-PGJ2, 30 nM AM580, or 30 nM 1,25-dihydroxyvitamin D3. THP-1 cells were treated for 48 hr with 40 ng/
ml TPA as indicated. Cells were incubated with fluorochrome-conjugated monoclonal antibodies and analyzed by flow cytometry as described
in the Experimental Procedures. A population of 10,000 viable cells was analyzed for each data point. The data are presented as the mean
fluorescence intensity of the counted population (A±D) or the change in fluorescence over the control population (E). For (C), expression of
PPARg mRNA in HL60 and CDM-1 cells was determined by Northern blotting. (A) Expression of CD11b and CD18 expression on HL60 cells.
(B) Expression of CD14 on HL60 cells. (C) Differential induction of CD14 and expression of PPARg in HL60 and CDM-1 cells. (D) Expression
of CD14 on THP-1 cells. (E) Expression of CD14 on primary human monocytes.
lesions are derived primarily from macrophages, the the macrophage response to high extracellular concen-
trations of oxLDL.lipid metabolism of these cells is of particular relevance
to human disease. Foam cells arise in a microenviron-
ment characterized by high local concentrations of oxi-
dized lipoproteins. Accordingly, we considered the pos- PPARg and RXR Ligands Stimulate Uptake
of OxLDL by THP-1 Cellssibility that expression of PPARg might be modulated
in response to such environmental conditions. THP-1 Since oxLDL stimulated PPARg expression, we specu-
lated that PPARg and RXR ligands may promote uptakecells were cultured for 5 days in the presence of LG268
and 50 mg/ml native or modified human LDL, and the of oxLDL by monocytic cells such as THP-1. Following
treatment with PPARg and RXR ligands, THP-1 cellsexpression of PPARg mRNA analyzed by Northern blot-
ting. While treatment of THP-1 cells with LG268 alone were incubated for 4 hr with increasing concentrations
of DiI-labeled oxLDL and cell-associated fluorescencehad no effect on expression of PPARg mRNA, simul-
taneous treatment with oxLDL and LG268 resulted in a quantitated by flow cytometry. As shown in Figure 5A,
treatment with either 15d-PGJ2 and LG268 or troglita-significant induction (Figure 4C). A smaller increase in
PPARg expression was observed whenTHP-1 cellswere zone and LG268 led to a significant increase in cell
association (a combination of binding and uptake) oftreated with oxLDL alone (data not shown). Surprisingly,
the ability to induce PPARg expression was specific for DiI-oxLDL. The specificity of this effect for modified lipo-
protein was verified using an an excess of unlabeledoxidatively modified LDL and was not observed with
either native or acetylated LDL (acLDL). We also exam- lipoprotein as competitor (Figure 5B). While an excess
of oxLDL abolished PPARg-induced association, nativeined PPARg expression in primary human peripheral
blood monocytes cultured in the presence or absence LDL did not compete. This specificity for modified LDL
is characteristic of macrophage scavenger receptors.of 50 mg/ml oxLDL. Figure 4C (right) shows that exposure
of human monocytes to oxLDL strongly induced PPARg In order to determine whether oxLDL was actually
internalized by PPARg-activated THP-1 cells, controlexpression. Primary monocytes were more responsive
than THP-1 cells to oxLDL and did not require LG268 and 15d-PGJ2/LG268-treated cultures were incubated
for 4 hr with 20 mg/ml DiI-oxLDL and examined by fluo-for maximal induction of PPARg. These results estab-
lished a link between oxLDL and the PPARg signaling rescence microscopy. As demonstrated in Figures 5C
and 5D, THP-1 cells treated with these activators showedpathway, and suggested that PPARg may play a role in
PPARg and Foam Cell Differentiation
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analyzed were able to induce significant expression of
mRNA encoding SR-A type I (Figure 6A) or SR-A type
II (data not shown). In fact, troglitazone antagonized the
induction of SR-A type I by TPA. Similar results were
obtained when 15d-PGJ2 was used as the PPARg ligand
(data not shown).
We further examined the effect of PPARg:RXR ligands
on surface expression of CD36 by flow cytometry. As
shown inFigure 6B, treatment of THP-1 cells and primary
human monocytes with either troglitazone or oxLDL alone
induced a significant change in CD36 expression. Con-
sistent with the Northern analysis (Figure 6A), simultane-
ous treatment with LG268 had a synergistic effect. We
also directly compared the ability of PPARg:RXR ligands
to modulate surface expression of CD36 and SR-A. Fig-
ure 6C demonstrates that while TPA was an effective
inducer of both CD36 and SR-A expression on THP-1
cells, the combination of 15d-PGJ2 and LG268 selec-
tively induced expression of CD36. Similar results were
obtained when troglitazone was used as the PPARg
Figure 4. PPAR Stimulates Differentiation and Is Induced by OxLDL ligand (data not shown). Thus, the differential effects of
in THP-1 Cells
TPA and PPARg:RXR activators on scavenger receptor
(A and B) PPARg and RXR ligands stimulate morphologic differentia-
mRNA expression are reflected in surface expressiontion of THP-1 cells. HL60 cells treated for 5 days with vehicle (A) or
of these proteins. We also analyzed expression of twowith 3 mM 15d-PGJ2 and 100 nM LG268 (B) were cytospun onto
additional candidate oxLDL receptors, CD68 and CD32.glass slides and stained with Diff-Quik. Objective magnification
1003. Oil red O staining demonstrated that the cytoplasmic vacu- No significant effect of PPARg and RXR ligands on ex-
oles in B correspond to cytoplasmic lipid (not shown). pression of either protein was observed (data not shown).
(C) OxLDL induces expression of PPARg in THP-1 cells and human Taken together, these results suggested that the ability
peripheral blood monocytes. Cell were cultured for 4 days in the
of PPARg and RXR ligands to stimulate binding andpresence of 100 nM LG268 and/or 50 mg protein/ml native LDL,
uptake of oxLDL in THP-1 cells might be mediated atacetylated LDL (acLDL), or oxidized LDL (oxLDL) as indicated. Total
least in part by the scavenger receptor CD36.RNA (15 mg per lane) was analyzed by Northern blotting using
32P-labeled cDNA probes.
PPARg:RXR Ligand-Induced Binding of OxLDL
to THP-1 Cells Is Mediated Primarily by CD36a significant increase in cytoplasmic fluorescence com-
To investigate whether the induction of CD36 and thepared to control cells. Thus, activation of the PPARg:
stimulation of oxLDL binding by PPARg:RXR ligandsRXR pathway in these cells stimulates both binding and
were linked, we utilized a monoclonal antibody to CD36uptake of oxLDL.
(OKM5) that has been demonstrated previously to inter-
fere with the binding of oxLDL (Endemann et al., 1993).PPARg and RXR Ligands Regulate Expression
Following 5 days of culture in the presence of 15d-PGJ2of the Scavenger Receptor CD36
and LG268, THP-1 cells were incubated for 3 hr at 48CThe ability of PPARg and RXR ligands to stimulate oxLDL
with 10 mg/ml DiI-oxLDL in the presence of OKM5 oruptake was likely to be the result of increased surface
control IgG monoclonal antibody and cell associationexpression of one or more macrophage scavenger re-
quantitated by flow cytometry. An excess of unlabeledceptors. The two receptors most conclusively linked to
oxLDL (200 mg/ml) served as a control for the specificityoxLDL uptake are CD36 and SR-A (type I and II). North-
of oxLDL binding. As shown in Figure 6C, the anti-CD36ern analysis was used to monitor expression of the
antibody was an effective inhibitor of DiI-oxLDL binding,mRNAs encoding these receptors in THP-1 cells follow-
resulting in a 65% reduction in total cell association anding treatment with various nuclear receptor ligands.
a 75% reduction in specific association (as defined byUnstimulated THP-1 cells do not express significant
competition with 20-fold excess of oxLDL). While it isamounts of mRNA for either CD36 or SR-A. TPA has
possible that other scavenger receptors may make mi-been reported previously to be an effective inducer of
nor contributions to PPARg:RXR-induced oxLDL asso-both CD36 and SR-A type I expression in THP-1 cells
ciation, these data indicate that the effect is mediated(Moulton et al., 1992; Yesner et al., 1996; Figure 6A). As
primarily by the scavenger receptor CD36.shown above for HL60 cells, TPA also induces expres-
sion of PPARg in THP-1 cells. Treatment of THP-1 cells
with either troglitazone alone or LG268 alone resulted The CD36 Promoter Is a Direct Target
of the PPARg:RXRa Heterodimerin a small increase in CD36 mRNA expression; however,
the combination of both ligands was almost as effective The observation that CD36 mRNA was increased upon
treatment with PPARg and RXR activators raised theas TPA. Moreover, the combination of troglitazone and
TPA led to an additive induction of CD36 mRNA expres- possibility that CD36 might be a direct target of the
PPARg:RXR heterodimer. To determine whether PPARgsion. Interestingly, none of the nuclear receptor ligands
Cell
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Figure 5. PPAR and RXR Activators Stimu-
late Binding and Uptake of OxLDL
(A) PPARg and RXR activators stimulate cell
association of DiI-oxLDL in THP-1 cells. Fol-
lowing 5 days of culture in the presence of
vehicle, 3 mM 15d-PGJ2 and 100 nM LG268,
or 15 mM troglitazone and 100 nM LG268,
THP-1 cells were replated and incubated for
4 hr at 378C with increasing concentrations of
DiI-oxLDL as described in the Experimental
Procedures. Cell-associated fluorescence was
quantitated by flow cytometry. Each point
represents the mean fluorescence of a 10,000
cell population. The experiment was repeated
three times with similar results.
(B) Oxidized but not native LDL competes for
PPARg:RXR-inducible cell association of DiI-
oxLDL to THP-1 cells. Following 5 days of
culture in the presence of vehicle or 3 mM
15d-PGJ2 and 100 nM LG268, cells were re-
plated and incubated for 4 hr at 378C in the
presence of 10 mg/ml DiI-oxLDL. A 30-fold
excess of unlabeled human oxLDL or native
LDL was added as a competitor as indicated.
The mean fluorescence 6 SE of the counted
populations from three independent experi-
ments is presented. The mean fluorescence
of the 15d-PGJ2/LG268-treated population
was assigned a value of 100%.
(C and D) PPARg and RXR ligands stimulate
uptake of DiI-labeled oxLDL by THP-1 cells.
Following 5 days of culture in the presence of vehicle (C) or 3 mM 15d-PGJ2 and 100 nM LG268 (D), THP-1 cells were replated and incubated
for 4 hr with 20 mg protein/ml DiI-oxLDL. The cells were washed, cytospun onto glass slides, and analyzed by fluorescence microscopy.
Objective magnification 403.
could function to regulate transcription of the CD36 pro- To confirm that this site was mediating the observed
induction of the CD36 promoter by PPARg:RXRa, wemoter, the region corresponding to 2273 to 147 of the
CD36 promoter (Armesilla and Vega, 1994) was cloned constructed a second CD36 promoter-luciferase re-
porter containing the sequence from 2263 to 147,into the luciferase reporter vector pGL-BASIC (2273/
luc).This construct wascotransfectedwith CMX-mPPARg which lacks the PPARg binding site (2263/luc). The
2263/luc construct showed minimal responsiveness toand CMX-hRXRa expression vectors into CV-1 cells.
Following transfection, the cells were treated with vehi- PPARg (Figure 7A). Collectively, these results suggest
that the PPARg:RXRa heterodimer modulates CD36cle or the PPARg-specific ligand BRL49653. Figure 7A
demonstrates that the PPARg:RXRa heterodimer acti- gene expression through direct interaction with the
proximal promoter.vated transcription of the 2273/luc construct in a ligand-
dependent manner.
The PPARg:RXR complex activates transcription of PPARg Is Expressed in the Foam Cells
of Atherosclerotic Lesionstarget genes by binding to DR-1 (direct repeat with one
nucleotide spacer) type hormone response elements The above findings raise the intriguing possibility that
PPARg may be involved in the regulation of foam cell(Kliewer et al., 1992b). We analyzed the promoter region
of the CD36 gene (Armesilla and Vega, 1994) and identi- lipid metabolism in vivo. A pivotal question, then, is
whether PPARg is actually expressed in the foam cellsfied a sequence (2273 to 2260) with homology to a
DR-1 motif (Figure 8B). The ability of a synthetic oligonu- of atherosclerotic lesions. In fact, very few transcription
factors have ever been shown to be present at detect-cleotide spanning this region to bind PPARg was investi-
gated by gel mobility shift assay using nuclear extracts able levels in foam cells. Expression of PPARg protein
in atherosclerotic lesions was examined by immunohis-prepared from 3T3-F442A adipocytes and THP-1 cells.
As shown in Figure 7B, a single nucleoprotein complex tochemistry using sections of aorta from a mouse that
carries human apoB and apo(a) transgenes and lackswas bound by the CD36 DR-1 oligonucleotide using
either nuclear extract. This complex was competed by a expression the LDL receptor (Sanan et al., 1998). These
mice develop atherosclerosis spontaneously at a young50-fold excess of unlabeled CD36 DR-1 oligonucleotide
(spf), but not by a similar excess of an oligonucleotide age when fed a normal diet. Subscapular brown adipose
tissue was used a control for PPARg expression. Aswith a mutation in the DR-1 site (mut). Moreover, the
complex was abolished and a supershift formed when seen in Figure 8, strong nuclear staining (brown) of the
adipocytes is observed with PPARg antisera (Figure 8B)incubated with antiserum to PPARg (Figure 7B) and
RXRa (data not shown), but not antiserum to PPARa. but not with preimmune sera (Figure 8A). The aortic
sections shown in Figures 8C, 8D, and 8E show athero-Thus, the CD36 promoter contains a bona fide binding
site for the PPARg:RXRa complex. sclerotic lesions characterized by the accumulation of
PPARg and Foam Cell Differentiation
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Figure 6. Regulation of Scavenger Receptor
Expression by PPARg and RXR Ligands
(A) Differential regulation of macrophage
scavenger receptor mRNA expression by nu-
clear receptor ligands. THP-1 cells were cul-
tured for 6 days in the presence of 100 nM
LG268, 15 mM troglitazone, 30 nM 1,25-dihy-
droxyvitamin D3, and/or for 24 hr in the pres-
ence of 40 ng/ml TPA. Total RNA (15 mg per
lane) was analyzed by Northern blotting using
32P-labeled cDNA probes.
(B) Regulation of surface CD36 expression on
THP-1 cells and primary human monocytes
by PPARg and RXR ligands. THP-1 cells were
treated for 5 days with 5 mM BRL49653, 3 mM
15d-PGJ2, and 100 nM LG268 as indicated,
or for 48 hr with 40 ng/ml TPA. Cells were
analyzed by flow cytometry using unconju-
gated anti-CD36 and FITC-conjugated anti-
IgG. A population of 5000 viable cells was
analyzed for each treatment. Data are pre-
sented as the difference in mean fluores-
cence between anti-CD36 antibody and con-
trol IgG.
(C) Regulation of surface CD36 and SR-A type
I/II expression on THP-1 cells by PPARg and
RXR ligands. THP-1 cells were cultured for 5 days in the presence of 100 nM LG268 and 3 mM 15d-PGJ2, or for 48 hr with 40 ng/ml TPA and
analyzed by flow cytometry using unconjugated anti-CD36 and anti-SR-A type I/II antibodies as in (B).
(D) Inhibition of PPARg:RXR-stimulated oxLDL association by a monoclonal antibody to CD36. THP-1 cells were treated for 5 days with vehicle
or 3 mM 15d-PGJ2 and 100 nM LG268, washed, and incubated for 3 hr at 48C in the presence of 10 mg/ml DiI-oxLDL. Unlabeled oxLDL (200
mg/ml), anti-CD36 monoclonal antibody (OKM5) orcontrol IgG monoclonal antibody was added as indicated. The cell-associated fluorescence 6
SE of the counted populations from two independent experiments is presented. The fluorescence of the 15d-PGJ2/LG268 treated population
in the absence of competitor was assigned a value of 100%.
macrophage-derived foam cells and lipid within the sub- collectively suggest that PPARg may play a role in the
pathogenesis of atherosclerosis.endothelial space. In contrast to the normal cellular
components of the vessel wall, the foam cells within
these lesions show remarkably strong nuclear staining
for PPARg (Figures 8C, 8D, and 8E). Discussion
The induction of PPARg expression by oxLDL expo-
sure, the ability of PPARg:RXR ligands to promote Coronary artery disease is the leading cause of death
in industrialized societies. A detailed understanding ofmonocyte differentiation and uptake of oxLDL, and the
high level of expression of PPARg in foam cells in vivo the molecularand cellular events that underlie formation
Figure 7. The CD36 Promoter Contains a
Functional Binding Site for the PPARg:RXRa
Heterodimer
(A) The PPARg:RXRaheterodimer activates the
CD36 promoter. CV-1 cells were transfected
with 2273/luc or 2263/luc reporter; CMX-b-
gal, CMX-mPPARg1, and CMX-hRXRa; and
cultured in the presence or absence of 5 mM
BRL49653 as indicated. Average normalized
luciferase activity (arbitrary units) of triplicate
points is presented. The experiment was re-
peated three times with similar results.
(B) A DR-1 motif in the CD36 promoter binds
PPARg:RXRa from 3T3-F442A adipocyte and
THP-1 nuclear extracts. An alignment of the
CD36 DR-1 motif with the consensus DR-1
element is shown at top. Double-stranded
32P-labeled CD36 DR-1 oligonucleotide was
used as a probe in a DNA mobility shift assay
with 3T3-F442A adipocyte and THP-1 mono-
cyte nuclear extract. Antisera to PPARa or
PPARg was included in the binding reaction
(1:200 dilution) as indicated. Competitor oli-




Figure 8. PPARg Is Expressed in the Foam Cells of Atherosclerotic Lesions
Expression of PPARg protein was localized by immunohistochemistry using affinity-purified anti-PPARg antisera. Peroxidase activity was
visualized by DAB and sections were counterstained with 0.4% methylgreen.
(A and B) Subscapular brown adipose tissue stained with preimmune serum (A) or PPARg antibody (B). Objective magnification 403.
(C±E) Expression of PPARg in atherosclerotic lesions from the aorta of an 8-month-old LDLR2/2; Tg(apoB);Tg(apoa) mouse. Objective magnifica-
tion 403 for (C) and (D) and 1003 for (E).
of the atherosclerotic plaque is a prerequisite to the therein). The subset of genes important for macrophage
accumulation and metabolism of cholesterol and lipidrational design of therapeutics for this disease.
In this work, we have presented evidence implicating may be at least partially distinct from those important
for inflammatory and immune responses. Interestingly,the nuclear receptor PPARg in a novel signaling pathway
that regulates differentiation and lipid metabolism in expression of a number of growth factors and cytokines
has been reported to be influenced by oxLDL, includingmonocytic cells (Figure 9). PPARg is induced in mono-
cytes by exposure to oxLDL and is expressed at high TNFa, IL-8, IL1-b, and iNOS (Hamilton et al., 1995; Wang
et al., 1996). Our observation that oxLDL exposure in-levels in the foam cells of atherosclerotic lesions. More-
over, ligand activation of this receptor leads to a tran- duces PPARg expression suggests that PPARg may be
important for the modulation of gene expression in thisscriptional induction of the scavenger receptor CD36
and endows cultured monocytes with the ability to bind context. In fact, we have recently demonstrated that
certain oxidized lipid components of the oxLDL particleand internalize oxLDL. Together, these results suggest
that PPARg and its congeners may play an unexpected can function as endogenous activators of PPARg (Nagy
et al., 1998).This observation reveals a novel mechanismrole in the development of the atherosclerotic lesion.
Macrophages participate in diverse biologic processes, whereby oxLDL may modulate macrophage gene ex-
pression.including phagocytosis of pathogens and debris, anti-
gen presentation, and regulation of the immune response While the association of a PPAR signaling pathway
with macrophage lipid metabolism is unexpected, it fitsthrough cytokine production. Subspecialization of mac-
rophages likely involves distinct alterations in patterns well with the previously defined role for PPARg in adipo-
genesis. Although prior work has focused primarily onof gene expression. For example, the osteoclast is a
specialized macrophage-like cell that plays a central its role in adipocytes, it is likely that this nuclear receptor
also functions as a regulator of lipid homeostasis in cer-role in bone remodeling. In this cell, the vitamin D recep-
tor, another member of the nuclear hormone receptor tain other specialized cell types. Changes in lipid metab-
olismare a prominent feature of macrophage differentia-superfamily, functions to regulate a specific set of genes
involved in bone resorption (Ross et al., 1994). During tion into foam cells. Such changes include increased free
and esterified cholesterol content, increased content ofatherogenesis, the deposition of large amounts of
oxLDL within the arterial wall leads to the development lipoprotein oxidation products, expression of scavenger
receptors, 15-lipoxygenase and lipoprotein lipase, andof another functionally specialized type of macrophage,
the foam cell (Steinberg et al., 1989, and references increases in acyl CoA: cholesterol acyltransferase (ACAT)
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Figure 9. A Role for PPARg in Monocyte/
Macrophage Differentiation
and acid cholesterol-ester hydrolase activities (Stary et of SR-A, however, PPARg ligands antagonize induction
by TPA. A similar antagonism of PPARg ligands and TPAal., 1994, and references therein). In addition to the scav-
enger receptor CD36 (this work), the lipoprotein lipase has recently been shown to occur on the SR-A promoter
in U937 cells (Ricote et al., 1998). The uptake of oxLDLgene has also been shown to be a target for PPARg
(Schoonjans et al., 1996). in vivo likely requires integration of multiple signaling
pathways, and therefore, the net effect of PPARg andThere is strong evidence that both SR-A and CD36
participate in the uptake of oxLDL in vivo (Nozaki et al., RXR agonists on macrophage uptake of oxLDLmay vary
between different cellular and hormonal contexts. Our1995; Suzuki et al., 1997). While expression of SR-A
is restricted to macrophages, CD36 is expressed in a findings that CD36 is a direct target of PPARg, that
exposure to oxLDL induces PPARg expression, and thatnumber of other cell types, including mammary epithe-
lium and adipose tissue. This pattern of expression over- the oxLDL particle itself is a rich source of PPARg activa-
tors (Nagy et al., 1998), collectively suggest that PPARglaps significantly with that of PPARg. Interestingly, CD36
is induced during the differentiation of preadipocytes may play a role in foam cell formation. Clearly, in vivo
studies will be required to further address this possi-and has been suggested to function as a fatty acid
transporter in adipose tissue (Abumrad et al., 1993). bility.
Two groups have reported recently that PPARg activa-CD36 expression is up-regulated by long chain fatty
acids in preadipocyte cell lines (Sfeir et al., 1997), and tors such as 15d-J2 and thiazolidinediones can inhibit
production of certain inflammatory cytokines by TPA-has also been shown to be induced in murine models
of diabetes and in mice maintained on a high-fat diet and IFNg-activated macrophages in culture (Jiang et
al., 1998; Ricote et al., 1998). However, the molecular(Greenwalt et al., 1995). Recently, it was reported that
both native and modified LDL can induce CD36 expres- mechanism involved in this inhibition and the implica-
tions of these observations for the physiologic role ofsion in J774 macrophages by a transcriptional mecha-
nism (Han et al., 1997). All of these observations are PPARg in monocytic cells are not clear. We have shown
here that in undifferentiated myeloid precursors andconsistent with our identification of CD36 as a PPARg
target gene. resting monocytes PPARg functions as an inducer of
monocytic gene expression and differentiation. Thus,Previous work has demonstrated that expression of
both the SR-A and CD36 genes is induced by M-CSF control of gene expression by PPARg in this cell type
is likely to involve both positive and negative regulationand TPA in THP-1 cells (Moulton et al., 1992; Yesner et
al., 1996). Surprisingly, however, we find that expression of target genes and to depend on the activation state
of the cell.of these two proteins is differentially regulated by nu-
clear receptor pathways. CD36, but not SR-A, is tran- As an obligate heterodimeric DNA binding partner for
a number of nuclear receptors, RXR stands at the cross-scriptionally induced by PPARg agonists in THP-1 cells.
The combined stimulus of a PPARg agonist and TPA roads of multiple cellular signaling pathways (Yu et al.,
1991; Kliewer et al., 1992a; Leid et al., 1992). Interpretinghas an additive effect on CD36 expression. In the case
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monocytes from healthy volunteers were isolated using Vacutainerthe effects of RXR ligands in biological systems can
CPT cell separator tubes, purified by adherence to the culture dish,therefore be difficult. It is now clear that certain hetero-
and maintained in RPMI containing 10% autologous human se-dimers, such as PPAR:RXR, can be activated by an RXR
rum. AM580 (Biomol), 15-deoxy-D12,14-prostaglandin J2 (Cayman),
ligand in the absence of ligand for the partner receptor BRL49653 (Biomol), troglitazone (Sankyo), LG268 (Ligand Pharma-
(a permissive heterodimer), while others, such as the ceuticals),1,25-dihydroxyvitamin D3 (Biomol), andTPA (Sigma) were
added to the culture media in a minimal volume (,0.1%) of ethanolRAR:RXR heterodimer, can be activated by RXR ligand
or DMSO. NBT reductionassays were performedas described (Nagyonly in the presence of ligand for the partner (a nonper-
et al., 1995). Total RNA was isolated using TRIzol reagent (GIBCO-missive heterodimer; Kurokawa et al., 1994; Forman et
BRL) and Northern analysis was carried out as described (Tontonozal., 1995b; Chen et al., 1996; Minucci et al., 1997). In the
et al. 1994a). The cDNA probe used for detection of SR-A was a
case of PPAR:RXR, a number of studies have provided 215bp fragment derived from the SR-A collagen-like domain (Matsu-
compelling evidence that the transcriptional activity of moto et al., 1990). A cDNA probe encoding human ribosomal phos-
phoprotein PO was used as a control for loading and integrity ofthe heterodimer is maximal in the presence of ligands
RNA (Laborda, 1991).for both receptors (Kliewer et al., 1992b). In fact, recent
work has demonstrated that RXR-specific ligands have
OxLDL Cell Associationsimilar activity to PPARg ligands in biologic systems,
All lipoproteinswere obtained from Perimmune Inc. For oxLDL asso-
including the ability to stimulate adipogenesis in cul- ciation experiments, cells were pretreated with receptor ligands
tured cell lines and the ability to increase insulin sensitiv- for 5 days and replated in RPMI containing 2.0% resin-charcoal-
ity in animal models of diabetes (Mukherjee et al., 1997; stripped FCSand the indicated concentration of DiI-labeled oxidized
human LDL. Unlabeled oxidized human LDL and native human LDLTontonoz et al., 1997). The work presented here has in
were added as competitors as indicated. Cells were incubated atmany instances utilized the combination of a PPARg
378C, washed twice with PBS containing 0.5 mM MgCl2 and 0.5 mMligand and an RXR ligand in an effort to activate the
CaCl2, and analyzed by flow cytometry or fluorescence microscopy.PPARg pathway maximally. The possibility that a portion Anti-CD36 antibody inhibition experiments were performed as de-
of the effect of the RXR ligand on myelomonocytic cells scribed (Endemann et al., 1993). Cells were preincubated in the
is mediated by a permissive heterodimeric partner other presence or absence of anti-CD36 monoclonal antibody OKM5 (Or-
tho Diagnostics) or control IgG monoclonal antibody for 30 minthan PPARg cannot be excluded.
at 48C. DiI-oxLDL was added at a final concentration of 10 mgIt is tempting to speculate that the elucidation of a
(protein)/ml, and cells were incubated for an additional 2.5 hr at 48C,nuclear receptor signaling pathway involved in macro-
washed, and analyzed by flow cytometry.
phage lipid metabolism may open the door for therapeu-
tic intervention in this process. A receptor agonist or Flow Cytometry
antagonist that could specifically inhibit cholesterol up- Cells were washed with ice-cold PBS containing 0.5% BSA and
take by macrophages in the arterial wall would obviously incubated with fluorochrome-conjugated monoclonal antibody for
30±60 min on ice. For experiments using anti-CD36 and anti-SR-Ahave tremendous pharmacologic potential. It is impor-
antibodies,a secondincubation with FITC-conjugatedanti-immuno-tant to keep in mind, however, both the differential ef-
globulin monoclonal antibody was performed. Nonspecific mono-fects of PPAR and RXR ligands on the expression of
clonal antibody (anti-BrdU) or normal mouse IgG was used as a
individual scavenger receptors and the complexity of control. Cells were stained with propidium iodide to facilitate selec-
systemic oxidized cholesterol metabolism. While cho- tion of the viable cell population and analyzed on a Becton-Dickin-
lesterol accumulation by subendothelial macrophages son FACScan using CellQuest software. The monoclonal antibodies
used were: R-phycoerythrin (RPE)-conjugated anti-human CD14is pathologic, themajor site of systemic oxidizedcholes-
(clone TUK4, DAKO), RPE-conjugated anti-human CD11b (cloneterol clearance is the liver (Brown and Goldstein, 1983;
2LPM19c, DAKO), fluorescein isothiocyanate (FITC)-conjugatedNagelkerke et al., 1984). The efficiency of hepatic clear-
anti-human CD18 (clone MHM23,DAKO), and FITC-conjugatedanti-
ance of oxLDL probably explains why oxLDL does not immunoglobulin (DAKO). The anti-human CD36 monoclonal anti-
circulate at significant concentrations and is able to bodies (8A6 and OKM5) were generously provided by J. Barnwell
accumulate only in the microenvironment of the athero- (NYU Medical Center) and Ortho Diagnostics, respectively. The anti-
SR-A I/II antibody was a gift of C. Glass (UCSD) .sclerotic artery wall. Since the pathways that regulate
oxLDL uptake in arterial wall macrophages and Kupffer
Immunocytochemistrycells are likely tooverlap, it is possible that an antagonist
To prepare polyclonal anti-human PPARg antisera, an N-terminalof these receptors might actually raise systemic levels
fragment of hPPARg1 (amino acids 1±145, Greene et al., 1995) was
of oxLDL. Moreover, since the relationship between lipid expressed in bacteria as a glutathione S-transferase (GST) fusion
homeostasis and atherogenesis is complex, the influ- protein and purified by glutathione affinity chromatography. The
PPARg fragment was purified from the GST carrier by thrombinence of PPARg and RXR ligands on systemic fatty acid,
cleavage followed by FPLC. Rabbits were immunized by standardtriglyceride and cholesterol metabolism, as well as their
protocols. Total immunoglobulin was isolated from the crude anti-effects on macrophage cytokine production, must also
sera using the E-Z-Sep kit (Pharmacia) and immunoaffinity purifiedbe taken into account. Clearly, in vivo studies will be
using a resin prepared by coupling the N-terminal PPARg protein
required to determine whether agonists or antagonists fragment to Affigel 10/15 agarose beads (Bio-Rad). 3T3-L1 cells and
of the PPARg:RXR pathway have potential utility in the human peripheral blood monocytes were cultured in multichamber
wells and processed for indirect immunofluorescence as follows.treatment or prevention of atherosclerosis.
Cells were fixed in chilled acetone for 20 min. Antibodies were
diluted in 20 mM Tris (pH 7.5), 0.5 M NaCl, 2% BSA, and 2 % nonfat
dry milk. Affinity-purified rabbit anti-human PPARg antibody wasExperimental Procedures
applied at a dilution of 1:50 at 48C overnight followed by an FITC-
labeled donkey anti-rabbit IgG (Jackson) diluted 1:80 for 45 min.Cell Culture and RNA Analysis
HL60 and THP-1 cells were obtained from ATCC and cultured in For tissue localization studies, cryostat sections of paraformalde-
hyde fixed tissue samples of LDLR2/2;Tg(apoB);Tg(apoa) mice wereRPMI containing 10% fetal calf serum (Summit), penicillin, and strep-
tomycin in an atmosphere of 7% CO2. Human peripheral blood used (Sanan et al., 1998). Endogenous peroxidase was blocked with
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0.1 M periodic acid for 10 min. Affinity-purified PPARg antibody was (1994). Peroxisome proliferator-activated receptor g: adipose-pre-
dominant expression and induction early in adipocyte differentia-applied at 48C overnight at 1:100 dilution, followed by a biotinylated
tion. Endocrinology 135, 798±800.goat anti-rabbit IgG (Vector Labs; 1:300 dilution) for 45 min at room
temperature. ABC peroxidase (Vectastain Elite, Vector) was used Chen, J.Y., Clifford, J., Zusi, C., Starrett, J., Tortolani, D., Ostrowski,
according to the manufacturer's instructions. Peroxidase activity J., Reczek, P.R., Chambon, P., and Gronemeyer, H. (1996). Two
was visualized either by DAB or the Vector VIP (Vector) substrate. distinct actions of retinoid receptor ligands. Nature 382, 819±822.
Sections were counterstained with 0.4% methylgreen. Endemann, G., Stanton, L.W., Madden, K.S., Bryant, C.M., White,
R.T., and Protter, A.A. (1993). CD36 is a receptor for oxidized low
Gel Shift and Transfection Assays density lipoprotein. J. Biol. Chem. 268, 11811±11816.
Nuclear extract preparation and gel mobility shift assays were per- Forman, B.M., Tontonoz, P., Chen, J., Brun, R.P., Spiegelman, B.M.,
formed as described previously (Graves et al., 1992). The sequences and Evans, R.M. (1995a). 15-deoxy-D12,14-prostaglandin J2 is a ligand
of the oligonucleotides used were as follows (only one strand for the adipocyte determination factor PPARg. Cell 83, 803±812.
shown): CD36 DR-1, 59-GGGGTCAGTAAGTCAGAGGCCAG GGA-39; Forman, B.M., Umesono, K., Chen, J., and Evans, R.M. (1995b).
mutant, 59-GGGGTCAGTAAGTCAGTTTCAGGGA-39. The human CD36 Unique response pathways are established by allosteric interactions
promoter region from 2273 to 147 and from 2263 to 147 (Armesilla among nuclear hormone receptors. Cell 81, 541±550.
and Vega, 1994) was amplified from human placental DNA by PCR
Goldstein, J.L.,Ho, Y.K., Basu, S.K., andBrown, M.S. (1979). Bindingand cloned into pGL-Basic (Promega). Transfections were per-
site on macrophages that mediatesuptake and degradation of acet-formed in phenol red-free DMEM containing 10% resin-charcoal-
ylated low density lipoproteins. Proc. Natl. Acad. Sci. USA 76,stripped fetal calf serum by the lipofection method using DOTAP
333±337.
(Boehringer Mannheim). Luciferase and b-galactosidase assays
Graves, R.A., Tontonoz, P., and Spiegelman, B.M. (1992). Analysiswere carried out as described (Forman et al., 1995a).
of a tissue-specific enhancer: ARF6 regulates adipogenic gene ex-
pression. Mol. Cell. Biol. 12, 1202±1208.
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